# A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer

> **NCT00116753** · PHASE2 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 460 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Degarelix
- **DRUG:** Degarelix
- **DRUG:** Degarelix

## Key facts

- **NCT ID:** NCT00116753
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 460 (ACTUAL)
- **Last updated:** 2010-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00116753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00116753, "A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00116753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*